Taiwan biopharma that developed and sells Besremi (ropeginterferon alfa-2b), a treatment for the blood cancer polycythemia vera.
Taiwan biopharma that developed and sells Besremi (ropeginterferon alfa-2b), a treatment for the blood cancer polycythemia vera.
Earns almost entirely from one injectable drug for a rare blood cancer, so revenue depends on how many patients are started on it and how long they stay on treatment, plus insurer coverage. It launched the drug itself in the US after the 2021 FDA approval and uses partners in some other markets.
In one line: A small, single-franchise specialty biotech.
Moat: narrow (IP / patents, regulatory licence). Patent-protected, FDA/EMA-approved biologic with limited direct alternatives for its indication.
Headquarters: Taipei, Taiwan · Founded: 2003
Size PharmaEssentia (6446.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $15.0B, the 37th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$1,245 on 18 Nov 2026.
Performance Over six months the shares gained 67.2%, against +4.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 78.2% over the last twelve months (peer median +14.7%); the operating margin is 40.4% (peer median 21.3%).
Valuation It trades at 31.9× forward earnings against a peer median of 24.1× (8th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +95%, so the hurdle is -71 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 44.5 points above its cost of capital (7.5% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$24.6B | NT$15.6B | NT$9.73B | NT$5.11B | NT$2.88B |
| Revenue growth | — | +61% | +91% | +77% | — |
| Gross profit | NT$22.5B | NT$13.7B | NT$8.31B | NT$4.34B | NT$1.95B |
| EBITDA | NT$10.4B | NT$5.33B | NT$2.10B | -NT$1.64B | -NT$1.80B |
| Net income | NT$9.08B | NT$5.05B | NT$2.97B | -NT$624M | -NT$1.37B |
| Free cash flow | NT$6.87B | NT$3.37B | NT$1.67B | -NT$2.03B | -NT$1.83B |
| Capital expenditure | NT$3.58B | NT$2.01B | NT$932M | NT$1.36B | NT$321M |
| Total debt | NT$1.11B | NT$856M | NT$965M | NT$1.20B | NT$1.57B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| PharmaEssentia 6446.TW | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 9.2× | -13.1% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 17.5× | 1.6% |
| Incyte INCY | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% |
| Protagonist Therapeutics PTGX | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6446.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | 0.0% | +6.1% | 6th lowest of 21 |
| 6-month return | +67.2% | +4.4% | 2nd highest of 21 |
| Distance from 52-week high | -24.3% | -6.8% | 7th lowest of 21 |
| Revenue growth (TTM) | +78.2% | +14.7% | 2nd highest of 21 |
| Operating margin | 40.4% | 21.3% | highest of 21 |
| Forward P/E | 31.9× | 24.1× | 8th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 23.7% | 0.8% | 7th most demanding of 19 |
| Growth delivered (Del g) | +94.8% | +12.3% | 2nd highest of 19 |
| Hurdle (Req g minus delivered) | -71.1 pp | -11.2 pp | 2nd least demanding of 19 |
| ROIC minus cost of capital | +44.5 pp | +7.2 pp | 3rd highest of 21 |
| EV / EBITDA | 44.5× | 17.1× | 3rd most expensive of 17 |
| Net debt / EBITDA | -2.5× | 0.3× | 2nd least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |
| Yunnan Baiyao 000538.SZ | China | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% | +4.7% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $14.9B | -7% | +14% | -43% | n/a | n/a | n/a |
| Ipsen IPN.PA | France | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% | +7.2% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% | +13.1% |
| Exelixis EXEL | United States | $16.7B | +37% | +9% | 40% | 17.7× | -3.8% | +18.6% |
| Laurus Labs LAURUSLABS.NS | India | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% | +7.3% |
| Ascendis Pharma A/S ASND | United States | $16.9B | +12% | +94% | 18% | 28.0× | 19.2% | +152.4% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% | +33.6% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.8B | +18% | +24% | 17% | 30.0× | n/a | n/a |
| Shionogi & 4507.T | Japan | $17.6B | +3% | +46% | 29% | 11.8× | 0.2% | +11.0% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% | +12.1% |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% | +5.4% |
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% | +12.6% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% | +11.3% |
| Innovent Biologics 1801.HK | Hong Kong | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% | +26.8% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $11.6B | -4% | -19% | 19% | 40.7× | 24.9% | +6.8% |
| Mankind Pharma MANKIND.NS | India | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% | +18.1% |
| Alnylam Pharmaceuticals ALNY | United States | $20.0B | -50% | +56% | 20% | 21.2× | 0.5% | +49.8% |